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CessationWe update an earlier review of smoking bans and heart disease, restricting attention to admissions for
acute myocardial infarction. Forty-ﬁve studies are considered. New features of our update include consid-
eration of non-linear trends in the underlying rate, a modiﬁed trend adjustment method where there are
multiple time periods post-ban, comparison of estimates based on changes in rates and numbers of cases,
and comparison of effect estimates according to post-ban changes in smoking restrictiveness. Using a
consistent approach to derive ban effect estimates, taking account of linear time trends and control data,
the reduction in risk following a ban was estimated as 4.2% (95% conﬁdence interval 1.8–6.5%). Excluding
regional estimates where national estimates are available, and studies where trend adjustment was not
possible, the estimate reduced to 2.6% (1.1–4.0%). Estimates were little affected by non-linear trend
adjustment, where possible, or by basing estimates on changes in rates. Ban effect estimates tended to
be greater in smaller studies, and studies with greater post-ban changes in smoking restrictiveness.
Though the ﬁndings suggest a true effect of smoking bans, uncertainties remain, due to the weakness
of much of the evidence, the small estimated effect, and various possibilities of bias.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Sargent et al. (2004) published the ﬁrst study of the effects of
smoking bans on heart disease, reporting a 40% reduction in hospi-
tal admissions from acute myocardial infarction (AMI) in Helena,
Montana, USA following the introduction of a local law banning
smoking in public places and workplaces. In 2011 we reviewed
the evidence then available, based on twenty-four studies (Lee
and Fry, 2011). We noted ‘‘major weaknesses in many studies
and meta-analyses, including failure to consider data from control
areas or existing trends in AMI rates, incorrect estimation of vari-
ability, and use in some meta-analyses of results for population
subsets or estimates apparently unrelated to the data reported’’.
Using a consistent approach to derive estimates of the ban effect,
and taking account of time trends and control data, our analyses
indicated a much smaller reduction in risk of heart disease
following a ban than the reductions of 10–19% claimed in some
other meta-analyses (Glantz, 2008; Lightwood and Glantz, 2009;
Mackay et al., 2010; Meyers et al., 2009), reductions which we
demonstrated were implausibly large considering likely changesin smoking habits and passive smoke exposure. Preferring national
to regional estimates where available, we estimated a 5% reduction
(95% conﬁdence interval [CI] 3–8%), which became 2.7% (2.1–3.4%)
when we omitted estimates where trend adjustment was not
possible.
Since our review (Lee and Fry, 2011), publications have prolifer-
ated, the current review being based on about twice as many pub-
lications as considered earlier. Our updated review has some new
features. First, we restrict attention to admissions from AMI, or
near equivalent endpoints. Evidence relating to mortality will be
considered later in a separate publication based on work currently
ongoing.
Secondly, as a recent paper (Barr et al., 2012) reported that esti-
mates of the ban effect adjusted for pre-ban non-linear trends in
rates may substantially differ from those adjusted only for linear
trend, we also derive study-speciﬁc estimates adjusted for non-
linear trend. This can only be attempted where the run of data
pre-ban is sufﬁciently long.
Third, we modify the method used to adjust for trend where
data are available for multiple periods post-ban. Earlier (Lee and
Fry, 2011), we derived the ban effect estimate by comparing the
total numbers of deaths observed post-ban with that predicted at
the midpoint of the post-ban periods based on the underlying
trend pre-ban. Here, we ﬁt a model that incorporates information
from both the pre-ban and post-ban trend, inference being based
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post-ban. The two approaches produce identical estimates where
there is only one post-ban period. The modiﬁed approach allows
us to ﬁt non-linear forms for the trend, such as the quadratic.
Fourth, we test the validity of an assumption we used earlier
(Lee and Fry, 2011). In these analyses, where data for a run of sim-
ilar periods (usually years) were available pre-ban, we estimated
the ban effect based on numbers of cases, assuming that linear
trend adjustment would automatically take into account changes
in population size. This assumption is not necessarily valid, so
we have also carried out analyses based on trends in rates. This
often involved obtaining population data from other sources.
Finally, we also include results of meta-analyses comparing ban
effect estimates according to measures of the change in smoking
restrictiveness following the ban. This better reﬂects the situation
where bans may vary in the extent to which they limit smoking,
and may be conducted against a background of various levels of
existing restrictiveness.2. Methods
2.1. Literature searches
Published studies and reviews relating smoking bans to risk of
AMI (or heart disease) additional to those considered earlier (Lee
and Fry, 2011) were sought from PubMed searches (January 1st
2009 to September 30th 2013) using the terms described by
Mackay et al. (2010), and also from papers cited in relevant
publications.2.2. Quantifying levels of restrictiveness
Except for local US studies, and for studies presenting overall
results based on multiple bans in different locations, we sought
published scores for restrictiveness before and after the ban, using
for US studies the method of Chriqui et al. (2002) without pre-
emption (as explained below), or a modiﬁcation of it (American
Lung Association, 2009), and for European studies the method of
Joossens and Raw (2006), re-expressing the scores as percentages.
Although the different ratings are not strictly comparable, this
method gives a reasonably detailed assessment of the legislation
in a variety of different environments, and of the level of change
expressed by the introduction of the ban. Where published scores
were unavailable, we conducted internet searches to supplement
the descriptions of the ban given in the study publication(s), and
estimated the scores using the Chriqui system.
The system of Chriqui et al. (2002) allocated a score of 4 points
for each of seven locations (government worksites, private work-
sites, schools, childcare facilities, restaurants including bar areas
of restaurants, retail stores and businesses, recreational and cul-
tural facilities), a bonus point for restrictions on outdoor smoking
restrictions in four of the locations (including outdoor seating at
bars and taverns under the restaurant category), and a further 5
points each for systems of penalties and enforcement, giving a
maximum score of 42 points. Points were deducted if states pre-
empted stricter local laws. Chriqui et al. (2002) gave ratings for
all states annually for 1993–1999, both with and without adjust-
ment for pre-emption, and the annual reports of the American
Lung Association published ratings without pre-emption for
2003–2006 (e.g., American Lung Association, 2008). In a later
report (American Lung Association, 2009), a modiﬁcation to the
rating system gave 4 points to each of the original categories,
and allocated 4 points each to bars/taverns (in addition to the 4
points for restaurants and their bar areas) and to casinos where rel-
evant, giving a maximum of 40 points in states without casinos, or44 points in states with casinos. Scores were then adjusted down
for pre-emption or up according to the percentage of the popula-
tion covered by local ordinances. Ratings under the modiﬁed sys-
tem are available up to 2013 (e.g., American Lung Association,
2013).
The Tobacco Control Scale, introduced by Joossens and Raw
(2006), included a section on smoke-free work and public places.
A score of 10 points was awarded for workplaces (excluding cafes
and restaurants), 8 points for cafes and restaurants, and 4 points
for other public places (trains, other public places and educational,
health, government and cultural places), giving a maximum of 22
points. Ratings were given for 30 European countries in 2005,
which have twice been updated (Joossens and Raw, 2007, 2011),
although referring to ‘‘bars’’ rather than ‘‘cafes’’. Ratings using the
same scheme were also given by Nguyen et al. (2012) for 11
European countries, annually from at least 1990–2010.
2.3. General approach
In many ways, the approach used is similar to that we used our
earlier (Lee and Fry, 2011). Thus:
 We estimate the effect of the ban by comparing the observed
number of AMI cases post-ban with that expected in the
absence of a ban, referring to the ratio as the ‘‘ban effect’’ or
the ban relative risk (RR).
 We consider it essential to account for the tendency for the risk
of AMI to vary seasonally by year (Ornato et al., 1996), by com-
paring numbers pre- and post-ban for whole years or the same
periods in a year (e.g., June to November), or by using results
which have adjusted for season or factors believed to cause
seasonal variation (e.g., temperature, humidity and inﬂuenza
rates). Studies taking no account of seasonal variation, e.g.,
comparing ﬁve months pre-ban and ﬁve months post-ban, are
rejected.
 Where possible, we attempt to adjust for any underlying time
trend in AMI rates. One method of doing this uses data for a
control population where trends are likely to be similar.
Another requires data for multiple similar time periods, in order
to estimate the trend. Where estimates can be obtained both by
use of a control population and by adjusting for trend, we prefer
to use the former as the shape of the trend is not always
well-deﬁned. However, results are presented based on both
approaches.
 Consideration should be given to speciﬁc factors that might
affect the time trend, such as changes in diagnostic criteria.
 As the great majority of studies consider the post-ban period as
starting immediately or just after the ban, we derive estimates
on this basis where possible.
 Where a study provides data for multiple control populations,
the ban effect is generally estimated from the combined control
data. However, control populations with obvious weaknesses
may be excluded.
 Some studies report results for subgroups by sex, age, or smok-
ing habit. For consistency, the estimates we use in our meta-
analyses are always based on the result for the whole study
population, and not on that for subsets. However, we summa-
rize the availability of such data. Exceptionally, where studies
present results relating to different ban times in different areas,
we report these separately.
 The mathematical methods we use assume that the effect of a
ban is to multiply the risk of AMI by a given factor, with the fac-
tor invariant of the length of time post-ban. The validity of this
assumption is investigated by comparing the estimates of the
magnitude of the ban effect in studies with shorter and longer
post-ban periods.
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the introduction. Thus:
 We do not consider mortality and restrict attention to admis-
sion rates for AMI or near equivalents including AMI discharges,
Medicare claims, and incidence, as well as admissions from
acute coronary syndrome (ACS), admissions from acute coro-
nary events (ACE), and sudden circulatory arrest (SCA).
 We test the effect of adjusting for non-linear as well as linear
trend, where the data are sufﬁcient to attempt this.
 We use a modiﬁed method to adjust for time trend, where there
are multiple periods post-ban.
 We calculate trend-adjusted RRs, not only based on numbers of
cases, but also on rates. Where necessary, we sought relevant
population data to estimate rates from numbers (or vice versa).
If not given in the study publication(s), the population data
were obtained from the WHO mortality database, or from a rel-
evant government website.
2.4. Estimating the ban effect
2.4.1. No control data and no trend information present
The RR associated with a ban, and the variance of its logarithm,
are estimated by:
RR1 ¼MTA=MTB ð1aÞ
and
V1 ¼ ð1=NTAÞ þ ð1=NTBÞ ð1bÞ
where M refers to the mean number of cases per year (or period of
interest), N refers to the total number of cases, the subscripts A and
B refer to the period after and before the ban, and the subscript T
refers to the test (ban) area.
The 95% CIs are estimated by
RRL1;RRU1 ¼ expðlogRR1  Z
ﬃﬃﬃﬃ
V
p
1Þ ð1cÞ
where Z is the standard normal deviate corresponding to 0.025.
Though seasonal effects are taken into account, provided the peri-
ods considered cover the same months of the year, no account is
taken of any underlying trend pre-ban, so estimates using formula
1 are considered less reliable than those taking trend into account.
2.4.2. Control data present
The RR and the variance of its logarithm are estimated by
RR2 ¼ ðNTA=NCAÞ=ðNCB=NTBÞ ð2aÞ
where the subscript C refers to the control (no ban) area, and
V2 ¼ ð1=NTAÞ þ ð1=NTBÞ þ ð1=NCAÞ þ ð1=NCBÞ ð2bÞ
with the lower and upper 95% CI of RR1 estimated by
RRL2;RRU2 ¼ exp ðlogRR2  Z
ﬃﬃﬃﬃﬃﬃ
V2
p
Þ ð2cÞ
These formulae assume that the lengths of the pre- and post-
ban periods for the test area are the same as for the control area,
so seasonal effects automatically cancel out. Any underlying trend
is accounted for by assuming that the trend in the control area
would also have been observed in the test area in the absence of
a ban.
2.4.3. No control data, and adjustment for linear trend possible
Where data are available on the number of cases occurring in
successive periods pre-ban and in one or more periods post-ban,
Poisson log-linear regression analysis (Draper and Smith, 1998)
was performed using SAS Version 9.2 (SAS Institute Inc., 2009).
The log of the number of deaths seen pre- and post-ban wasmodeled as a linear effect over year, with a dummy variable
included, set to zero pre-ban and one post-ban. With no effect of
the ban, the estimate for this dummy variable should be zero.
However if there was an offset to the linear trend caused by the
ban, this estimate will give a value for the effect. As the Poisson
model in SAS models the deaths in terms of log number of deaths,
the ban effect, RR3, is given by the exponential of the estimate, with
the 95% CI derived from its standard error (SE3):
RRL3;RRU3 ¼ exp ðlogRR3  ZSE3Þ ð3Þ
The methodology assumes that each period covers the same
months of the year, so seasonal effects are not an issue.
Note that the methods described above (loosely referred to
below as formula 3) can also be applied where control data are
available, providing that pre-ban data are available for successive
periods, simply by ignoring the control area data.
The methodology described above is based on the numbers of
cases occurring in each period, ignoring changes in population size.
Where population data are available for each period, the method is
adapted by adding the log of the population as an offset to the
model. The relative risk and CIs are estimated from the dummy
variable as above.
2.4.4. No control data, and adjustment for non-linear trend possible
Where data are available on the number of cases for at least
three periods pre-ban and in one or more periods post-ban, the
same methods are used, except that the prediction equation
includes years squared as a quadratic term.
2.5. Meta-analyses
Independent RR estimates from multiple studies are combined
using random-effects meta-analysis (Littell et al., 2006) weighted
on the inverse of the variance of the RRs. Results of ﬁxed-effect
meta-analyses (SAS Institute Inc., 2009), conducted using weighted
linear regression with the SEs adjusted as recommended by Berlin
et al. (1993) are also shown.
Meta-analyses of AMI admission data (or near equivalent) are
conducted separately by type of estimate (i.e., based on formulae
1, 2 or 3) and overall. They also investigate variation by region,
study weight, the lengths of the pre-ban and post-ban periods,
change in restrictiveness following the ban, and the age range of
the population studied. Meta-analyses are also conducted exclud-
ing regional estimates where national estimates are available and
omitting estimates where trend adjustment was not possible.
The meta-analyses carried out were deﬁned in advance.3. Results
3.1. Literature searching
Initially, 57 studies were identiﬁed, published between 2004
and 2013. Two were rejected as no useful ban effect estimate could
be made (Marlow, 2012; Naiman et al., 2010), one as the endpoints
(ever AMI, ever coronary heart disease (CHD) or angina) were inap-
propriate (Lippert and Gustat, 2012) and ﬁve as only mortality data
were available (Dove et al., 2010; McAlister et al., 2010; Rodu et al.,
2012; Stallings-Smith et al., 2013; Villalbí et al., 2011). Two studies
were rejected as they compared pre-ban and post-ban periods of
only a few months covering different seasons of the year, with
no seasonal adjustment possible (Gudnason et al., 2009; Johnson
and Beal, 2013). The ﬁnal two studies rejected (Sargent et al.,
2012; Vander Weg et al., 2012) were longer term, involving bans
introduced in different regions at various times, with no seasonal
adjustment made or possible from the data presented. Of the 45
Table 1
Summary of location and timing for the 45 studies.
Study Reference(s) Locationb Timing of ban Data available relative to a bana
Before After
S1 Sargent et al. (2004) Helena, Montana, USA (vs Outside city) 5 Jun 02c Jun to Nov 98,99,00,01 Jun to Nov 02d
S2 Barone-Adesi et al. (2006, 2009a,b) Piedmont, Italy 10 Jan 05 Feb to Jun 02,03,04e Feb to Jun 05f
S3 Alsever et al. (2009) and Bartecchi et al. (2006) Pueblo, Colorado, USA (vs El Paso Countyg) 1 Jul 03 Jan 02 to Jun 03 Jul 03 to Jun 06
S4 Bullen et al. (2006) New Zealand 10 Dec 04 Dec 96 to Nov 04 Dec 04 to Nov 05
S5 Cronin et al. (2007, 2012) Southwest Ireland 29 Mar 04 Year ending 28 Mar 04 Years ending 28 Mar 05, 06, 07
S6 Heinz et al. (2007) Boise, Idaho, USA 1 Jul 04 2 years pre-ban 1 year post-ban
S7 Juster et al. (2007) and Loomis and Juster (2012) New York State, USA 24 Jul 03 95,96. . .02 04h,i
S8 Khuder et al. (2007) Bowling Green, Ohio, USA (vs Kent) Mar 02 Mar 99 to Feb 02 Mar 02 to Feb 05j
S9 Seo and Torabi (2007) Monroe County, Indiana, USA (vs Delaware County) 1 Aug 03 Aug 01 to May 03 Aug 03 to May 05
S10 Barnett et al. (2009) Christchurch, New Zealand Dec 04 03,04 05,06
S11 Cesaroni et al. (2008) Rome, Italy 10 Jan 05 02,03,04e 05
S12 Lemstra et al. (2008) Saskatoon, Saskatchewan, Canada 1 Jul 04 Years ending June 01,02,03,04e Year ending June 05
S13 Pell et al. (2008) Scotland End Mar 06 Jun 05 to Mar 06 Jun 06 to Mar 07
S14 Vasselli et al. (2008) Four areas, Italy 10 Jan 05 10 Jan to 10 Mar 02,03,04e 10 Jan to 10 Mar 05
S15 Gasparrini et al. (2009) Tuscany, Italy 10 Jan 05 02,03,04e 05
S16 Shetty et al. (2009, 2011) By region, USA Varies from 90 to 04 90,91. . .04k
S17 Villalbí et al. (2009) Barcelona, Spain 1 Jan 06 04,05 06
S18 Di Valentino et al. (2010, 2011a,b,c) Ticino, Switzerland 13 Apr 06 Years ending 12 Apr 04,05 Years ending 12 Apr 06,07
S19 Mathews, 2010 74 cities, USA Varies from 03 to 06 Year before each ban Year after each ban
S20 McMillen et al. (2010) Starkville, Mississippi, USA (vs Outside city) 20 May 06 29 Jul 04 to 19 May 06 20 May 06 to 7 Apr 09
Hattiesburg, Mississippi, USA (vs Outside city) 1 Jan 07 21 Apr 05 to 31 Dec 06 1 Jan 07 to 30 Jan 09
S21 Moraros et al. (2010) Delaware, USA (vs non-state residents) Nov 02 Q1 99 to Q3 02 Q1 03 to Q4 04l
S22 Sims et al. (2010) England 1 Jul 07 Jul 02 to Jun 07 Jul 07 to Sep 08
S23 Dautzenberg (2008), Séguret et al. (2013) and Thomas et al. (2010) France Feb 07,Jan 08 03,04,05,06 08,09m
S24 Bonetti et al. (2011) and Trachsel et al. (2010) Graubuenden, Switzerland (vs Lucernen) 1 Mar 08 Years ending Feb 07,08 Years ending Feb 09,10
S25 Barone-Adesi et al. (2011) Italy 10 Jan 05 02,03,04 05o
S26 Bruckman and Bennerr (2011) Ohio, USA 3 May 07 05,06 08,09i
S27 Bruintjes et al. (2011) Greeley, Colorado, USA (vs Outside city) Dec 03 Jul 02 to Nov 03 Dec 03 to Jun 06
S28 Ferrante et al. (2012) Santa Fe province, Argentina Aug 06 Aug 05 to Jul 06 Aug 06 to Jul 07
Buenos Aires city, Argentina Oct 06 Oct 05 to Sep 06 Oct 06 to Sep 07
S29 Gupta et al. (2011) Kanawha County, West Virginia, USA 95,00,03 Jan 00 to Sep 08p
S30 Hahn et al. (2011) Lexington, Kentucky, USA 27 Apr 04 01,02,03 05,06i
S31 Herman and Walsh (2011) Arizona, USA May 07 Years ending Apr 05,06,07 Year ending Apr 08
S32 Hurt et al., 2011, 2012 Olmsted County, Minnesota, USA 1 Jan 02,1 Oct 07 18 months before each ban 18 months after each ban
S33 North Carolina Tobacco Prevention and Control Branch (2011) North Carolina, USA 1 Jan 10 08,09 10
S34 Xuereb et al. (2011) Malta Apr 04 99 to 03 05 to 09i
S35 Barr et al. (2012) 387 counties in 9 states, USAq Varies from 00 to 07 Jan 99 to Dec 08p
S36 Christensen et al. (2012) Denmark 15 Aug 07 Years ending Aug 03,04,05,06,07 Years ending Aug 08,09
S37 de Korte-de-Boer et al. (2012) South Limburg, Netherlands 1 Jan 04 Jan 02 to Dec 03 Jan 04 to Jun 08r
S38 Head et al. (2012) Beaumont, Texas, USA (vs Tylers) Jul 06 Years ending Jun 05,06 Years ending Jun 07,08
S39 Huesch et al. (2012) New Jersey, USA 15 Apr 06 May-Mar 04,05 May-Mar 06t
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S40 Kent et al. (2012) Ireland 29 Mar 04 02 to 03 05 to 06
S41 Loomis and Juster (2012) Florida, USAu Jul 03 Jan 90 to Dec 06k
S42 Roberts et al. (2012) Rhode Island, USA Mar 05 03,04 06,07,08,09i
S43 Agüero et al. (2013) Girona, Spain 1 Jan 06 02,03,04,05 06,07,08
S44 Gaudreau et al. (2013) Prince Edward Island, Canadav 1 Jun 03w 98,99,00,01,02x 04,05,06,07,08i
S45 Sebrié et al. (2013) Uruguay 1 Mar 06 Mar 04 to Feb 06 Mar 06 to Feb 08
a Refers to the data used in our meta-analysis, other available data being mentioned in footnotes.
b Control location shown in brackets.
c Ban suspended 3 Dec 02.
d Data also available for year after ban suspended but not used.
e Data for earlier years ignored as diagnostic criteria changed.
f Data from later paper to Jun 07 ignored, as only available analysis includes 2001.
g Data for outside Pueblo city limits ignored as may have been affected by ban.
h Data from later paper to 2006 ignored as relevant detail not available.
i Data for year of ban ignored.
j Data for Jan and Feb 99, and Mar to Jun 05 not used to avoid seasonal effects.
k Analysis based on model-ﬁtting, with data by period not given.
l Q = quarter.
m Data for year between two stages of the ban ignored.
n Control data for Lucerne not used – see Appendix A.
o Incomplete data for 2006 ignored.
p Multiple bans so cannot deﬁne pre- and post-.
q Arizona, Delaware, Illinois, Massachusetts, Minnesota, New Jersey, New York, Ohio, Washington.
r Data relevant to a second ban (1 Jul 2008) not used – see Appendix A.
s Data for all Texas hospitals also available but not used as mixture of bans.
t Data for April each year not used. Also data for Jan-Mar 04 and May-Dec 07 not used to avoid seasonal effects.
u Data relevant to bans in two localities in Oregon (Corvallis 1998 and Eugene 2000) not used – see Appendix A.
v Data for control area, New Brunswick, ignored as not presented in suitable form.
w There was a minor extension to the ban 1 Jul 2006, which was found by the original author to have had no signiﬁcant effect.
x Data for 1995–1997 not used, as trend very different.
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Table 2
Age of population, endpoint used, availability of data for subgroups, and restrictiveness score details.
Study Reference(s)a Age Endpoint used Data also available by Rating systemb Restrictiveness score %
Before After Difference
S1 Sargent et al. (2004) 18+ AMI admissions
S2 Barone-Adesi et al. (2006) All AMI admissionsc Aged J 27 77 50
S3 Alsever et al. (2009) All AMI admissions
S4 Bullen et al. (2006) 15+ AMI admissionse C1f 45 88 43
S5 Cronin et al. (2012) 18+ ACS admissions J 14 95 82
S6 Heinz et al. (2007) All AMI admissions
S7 Juster et al. (2007) 35+ AMI admissions C1 45 88 43
S8 Khuder et al. (2007) 18+ CHD admissions
S9 Seo and Torabi (2007) All AMI admissions Smoking habit
S10 Barnett et al. (2009) 30+ AMI admissions Sex and age C1f 45 88 43
S11 Cesaroni et al. (2008) 35–84 ACE episodes Sex and age J 27 77 50
S12 Lemstra et al. (2008) All AMI discharges C1f 62 79 17
S13 Pell et al. (2008) All ACS admissions Sex and age J 5 95 91
S14 Vasselli et al. (2008) 40–64 AMI admissions Region, sex and age J 27 77 50
S15 Gasparrini et al. (2009) 30–64 AMI deaths or admissions J 27 77 50
S16 Shetty et al. (2011) All AMI admissions
S17 Villalbí et al. (2009) 25+ AMI discharges Sex and age J 23 68 45
S18 Di Valentino et al. (2010) All ACS admissionsg Sex and age Jh 27 50 23
S19 Mathews (2010) 65+ AMI claimsi
S20 McMillen et al. (2010) All AMI admissions
S21 Moraros et al. (2010) 18+ AMI discharges C1 40 93 52
S22 Sims et al. (2010) 18+ AMI admissions Sex and age J 5 95 91
S23 Séguret et al. (2013) 18+ ACS admissions Sex and age J 27 77 50
S24 Bonetti et al. (2011) All AMI admission and angiography Jh 27 50 23
S25 Barone-Adesi et al. (2011) All ACE admissions Sex and age J 27 77 50
S26 Bruckman and Bennerr (2011) All AMI dischargesj C1 29 93 64
S27 Bruintjes et al. (2011) All AMI admissions
S28 Ferrante et al. (2012) 18+ ACS admissions C1f,k 7 90 83
C1f,l 7 48 40
S29 Gupta et al. (2011) 18+ ACS admissions
S30 Hahn et al. (2011) 35+ AMI admissions Sex
S31 Herman and Walsh (2011) All AMI admissionse Areas with and without prior local ban C1 31 93 62
S32 Hurt et al. (2012) All AMI incidence Two bans separately
S33 North Carolina Tobacco Prevention and Control Branch (2011) 18+ AMI admissions Sex and age C2 15 53 38
S34 Xuereb et al. (2011) All ACS admissions Jm 0 77 77
S35 Barr et al. (2012) 65+ AMI admissions State and age
S36 Christensen et al. (2012) 30+ AMI admissions J 14 50 36
S37 de Korte-de-Boer et al. (2012) 20–75 SCA events J 5 41 36
S38 Head et al. (2012) All AMI discharges Race
S39 Huesch et al. (2012) All AMI admissions C1 48 86 38
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P.N. Lee et al. / Regulatory Toxicology and Pharmacology 70 (2014) 7–23 13studies accepted, 21 had been considered in our earlier review (Lee
and Fry, 2011). Additional data were available from later publica-
tions in some studies considered earlier.
3.2. Study characteristics
Table 1 gives, for each study, the relevant references, the
location of the study area (and the control area if applicable), the
timing of the ban, and the periods pre- and post-ban for which data
are available. The studies are identiﬁed by codes S1 to S45. Studies
were conducted in 15 countries. National estimates are available
for seven European countries – Denmark, England, France, Ireland,
Italy, Malta and Scotland – and also for New Zealand, Uruguay and
the USA. Only regional estimates are available for Argentina,
Canada, Netherlands and Switzerland. There are regional, as well
as national, studies for Ireland, Italy and particularly the USA.
Twenty-two studies were conducted in the USA, and ﬁve in Italy,
with other countries having only one or two studies. The studies
in the USA varied widely in their coverage, with one study (S16)
conducted nationally, one (S19) in 74 cities, one (S35) in multiple
states, seven (S7, S26, S31, S33, S39, S41, S42) in single states,
and a further 12 in speciﬁc locations within a state. Of the 37
studies which considered a single ban, all the bans occurred in
2002–2010, with the number of studies for each of those years
being, respectively, 3, 6, 9, 6, 7, 4, 1, 0 and 1. There were eight stud-
ies which considered effects of multiple ordinances (either in mul-
tiple locations or successive ordinances in individual locations).
Table 2 presents further study details on the age of the popula-
tions studied, the endpoint used in our analyses, the availability of
estimates for study subsets, and the restrictiveness scores.
Eighteen of the studies considered the whole age range, and a
further 19 studies only excluded children or younger adults where
the risk of heart disease would have been quite small. Six studies
considered a deﬁned age range limited below and above, such as
30–64 years. Two studies, both based on Medicare enrollees,
restricted attention to ages 65+ years.
Although only the combined results from each study are consid-
ered in our analyses, 17 of the studies presented results for study
subsets. Ten presented results by age and sex (one also by loca-
tion), one by age only, one by sex only, one by race only, one by
location only, and one by location and age. One presented results
separately for smokers and non-smokers, and one separately for
multiple bans.
Of the 45 studies, 34 had AMI as the main endpoint, 24 referring
to AMI admissions, ﬁve to AMI discharges, two to AMI incidence,
and one each to deaths or admissions, claims, or admissions and
angiography. ACS admissions was the main endpoint used in seven
studies, with four other endpoints each used in one study: CHD
admissions; ACE; ACE admissions; and SCA events. Eight studies
provided data for alternative heart disease endpoints.
Table 2 presents pre-ban and post-ban restrictiveness scores
and their difference, scores being unavailable for 14 studies. The
32 sets of scores for the remaining 31 studies (S28 having two sets)
have been derived by three methods: the Chriqui system (Chriqui
et al., 2002) (14 studies), the modiﬁed Chriqui system (American
Lung Association, 2009) (1 study) and the Joossens and Raw system
(Joossens and Raw, 2006) (17 studies), and then expressed as a per-
centage of the maximum score possible. Pre-ban scores range from
0% to 62% (median 27%), post-ban scores from 41% to 95% (median
79%) and differences from 17% to 91% (median 50%). The largest
differences, of 91%, were for the UK (studies S13 and S22).
Further details of each study are given in Appendix A. Apart
from giving details of the nature of the ban and the results reported
by the authors, reference is made to weaknesses in the original
estimates and to why (where relevant) some subsets of the study
results were rejected, and a clear description is given of how the
14 P.N. Lee et al. / Regulatory Toxicology and Pharmacology 70 (2014) 7–23main RR estimate we used was derived. Where relevant, comments
are made on the RRs used in some earlier reviews and meta-
analyses (Glantz, 2008; Institute of Medicine, 2010; Lightwood
and Glantz, 2009; Mackay et al., 2010; Meyers et al., 2009).3.3. Studies where adjustment for trend was not possible
In six studies, conducted in ﬁve countries, adjustment for time
trend was not possible, as there was no control area, or data for
only one time period pre-ban. Table 3 gives, for each study, the
mean number of cases pre- and post-ban, and the ban effect RR
derived using formula 1 (or in study S19 as provided by the
author). Of the seven RR estimates (study S28 presenting results
for two areas), six were below 1, ﬁve signiﬁcantly so (at p < 0.05),
with the random-effects meta-analysis estimate 0.91 (95% CI
0.84–0.99).3.4. Studies using control data
Eight studies, all in the USA, provided results for a control pop-
ulation where no ban was in force. Table 4 gives, for each study, the
number of cases pre- and post-ban in each area and the ban effect
RR derived using formula 2 (or in studies S27 and S38 the ratio of
the authors’ separate estimates of the post-ban decline in the ban
and the control areas). Of the nine RR estimates (study S20 pre-
senting results for two areas), all were below 1, four signiﬁcantly
so (at p < 0.05), with the random-effects meta-analysis estimate
0.80 (95% CI 0.68–0.95).3.5. Studies adjusting for linear trend
There were 31 studies without control data for which results
adjusted for linear trend were available, being either provided by
the authors themselves or derived by us. Thirteen studies were
conducted in the USA, with ﬁve in Italy, two each in Canada,
New Zealand, Spain and Switzerland, and one in each of ﬁve
countries. Table 5 gives, for each study, the numbers of cases in
each time period pre- and post-ban, and the ban effect RR derived
as described in Section 2.4.3, except where indicated. Of the 31
estimates, 26 were below 1, nine signiﬁcantly so (at p < 0.05),
and ﬁve were above 1, three signiﬁcantly. The random-effects
meta-analysis estimate is 0.97 (95% CI 0.95–1.00).
Of the studies with controls considered in Table 4, three
allowed an alternative estimate adjusted for linear trend using for-
mula 3. Table 6 compares the alternative and original ban effect
RRs. The alternative estimate was higher in two studies and lower
in one.Table 3
Effect of smoking bans on AMI admissions (or near equivalent) for studies where adjustm
Study Reference(s) Location Pre-ban per
Mean cases
S5 Cronin et al. (2012) South West Ireland 1216
S13 Pell et al. (2008) Scotland 3235
S19 Mathews (2010) 74 cities, USA –
S28 Ferrante et al. (2012) Santa Fe, Argentina 1612
Buenos Aires, Argentina 1699
S34 Xuereb et al. (2011) Malta 850
S40 Kent et al. (2012) Ireland 4072
Meta-analysis – random effects (n = 7 estimates)
a All estimates were calculated using formula 1, except where indicated.
b Same 10 months in year as for pre-ban data.
c Estimate by the author based on data for 74 cities, with the mean rate for 2000–20
d Heterogeneity chisquared = 65.20 on 6 d.f., p < 0.001.The estimates in Table 5 were based on the numbers of cases by
period pre- and post-ban. If the population were changing over
time, these estimates might be somewhat biased. Where rates
are available, an alternative estimate can be derived, based on rates
rather than numbers. Table 7 compares the estimates calculated
both ways for the 24 studies where both numbers of cases and
rates are available. The pairs of estimates are generally remarkably
similar, with 13 the same to two decimal places, and none differing
by more than ±0.02. This indicates that the approach based on
numbers we used earlier (Lee and Fry, 2011) is adequate. Since
populations or rates are not always available, we continue to use
estimates based on numbers for our main meta-analyses.3.6. Studies adjusting for quadratic trend
For those 17 studies considered in Table 5 with at least three
time periods pre-ban, Table 8 presents alternative estimates
adjusted for quadratic trend, with those adjusted only for linear
trend also presented for comparison. There is no strong evidence
of any systematic effect on the estimate, with ﬁve of the quadratic
estimates higher, 11 lower and one the same (to two decimal
places), compared to the linear estimates. The quadratic estimates
have wider 95% CIs, particularly in three studies (S2, S14, S15).
Because of this, the weight (inverse-variance) of the quadratic
estimates is lower than those of the linear estimates. The meta-
analysis estimates are similar, 0.96 (95% CI 0.93–0.99) using qua-
dratic adjustment, and 0.97 (0.95–0.99) using linear adjustment.3.7. Further meta-analyses
Table 9 presents results of ﬁxed-effect and random-effects
meta-analysis for all 47 estimates included in Tables 3–5, and also
results of meta-analyses either replacing some of the main analysis
estimated by alternatives included in Tables 6–8, or excluding var-
ious estimates from the analysis. It can be seen that in all eight
analyses, both ﬁxed and random estimates showed a modest ban
effect, ranging from a 2.5% reduction (RR = 0.975) to a 5.8% reduc-
tion (RR = 0.942). All these reductions were statistically signiﬁcant
at p < 0.05, though sometimes marginally so. The individual
estimates included in each analysis showed highly signiﬁcant
(p < 0.001) heterogeneity.
Based on the random-effects estimate, the main analysis, A1,
gave an RR of 0.958 (95% CI 0.935–0.982). Using the alternative esti-
mates from Table 6 (using formula 3 rather than 2) in analysis A2
had very little effect on the estimates. Using rates rather than num-
bers in analysis A3 slightly reduced the estimated decrease in risk
from bans, while using quadratic rather than linear estimates
slightly increased it (analyses A4 and A5). However, estimatesent for trend was not possible.
iod Post-ban period RR (95% CI)a
(yrs) Mean cases (yrs)
1 1020.33 3 0.84 (0.77–0.91)
10 monthsb 2684 10 months 0.83 (0.79–0.87)
Varies – Varies 0.97 (0.95–0.99)c
1 1277 1 0.79 (0.74–0.85)
1 1608 1 0.95 (0.88–1.01)
5 890 5 1.05 (0.95–1.15)
2 3876 2 0.95 (0.91–0.99)
0.91 (0.84–0.99)d
08 in the post-ban period being divided by that for the pre-ban period.
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itself had a 95% CI of almost ±0.025.
Excluding results from the main analysis had rather more effect,
whether excluding (to avoid double-counting) original estimates
where national estimates were available (analysis A6) or excluding
Table 6 results which did not adjust for trend (analysis A7). Both
exclusions seem scientiﬁcally appropriate and the net effect is to
reduce the main analysis reduction of 4.2% (RR = 0.958) to 2.6%
(RR = 0.974) (analysis A8).
Table 10 studies how the ban effect estimates vary by eight dif-
ferent factors. There was no evidence of variation signiﬁcant at
p < 0.05 by any factor studied, though there was some indication
of an effect for some.
Ban effects were greater (i.e., smaller RR) for the 10 estimates
with the least weight (<100), six of which were from the studies
summarized in Table 4 using control data. There was also some
evidence that the effect related to change in the restrictiveness
score, with a 4–5% reduction seen where the change in score was
by 40% or more, but no reduction seen where it was less than
40%. There was also some indication that estimated reductions
were greater in studies with a short pre-ban period, and in studies
conducted outside USA or Western Europe. No clear relationship
was seen with the length of the post-ban period, or with either
the lower or upper age limit of the populations studied.4. Discussion
4.1. Rapid increase in the number of publications
In our earlier review (Lee and Fry, 2011), we considered data
from 24 studies published between 2004 and 2011, three rejected
in our current analysis. Subsequently, in little over two years, the
number of studies has risen substantially, from 24 to 57 (with 12
rejected), illustrating the increasing number of bans and level of
interest in their effect.
4.2. Weaknesses of the studies and published estimates
As highlighted earlier (Lee and Fry, 2011), the estimates derived
by the authors of the source papers are based on a variety of meth-
ods, many suffering from weaknesses. These are discussed quite
fully in Appendix A, so here we merely summarize some of the
problems, including failure to take seasonal variation into account,
failure to use control data, failure to account for the underlying
trend pre-ban, basing estimates on selected subsets rather than
on the whole available population, failure to consider changes in
diagnostic criteria, and incorrect estimation of results. Also, there
is the possibility of publication bias, with studies ﬁnding no effect
of a ban possibly never being published, and bias due to ‘‘regres-
sion to the mean’’ if bans tend to be introduced, or studies
conducted, in areas with a high AMI rate, though this is more rel-
evant to local rather than national studies. Though publication bias
and regression to the mean are hardly relevant to the national
studies, they are quite plausible sources of bias in the small area
studies using control data (Table 4), and may help to explain their
greater apparent ban effect.
4.3. Need for a consistent approach
A consistent approach is clearly needed, and to achieve this we
derived our own estimates based on the whole available data, and,
where possible, adjusting for the underlying time trend, using con-
trol data if available or, if not, based on data for multiple pre-ban
periods. We rejected studies where seasonal variation could not
be taken into account, and studies seriously biased for other
Table 5
Effect of smoking bans on AMI admissions (or near equivalent) for studies without control data for which adjustment for linear time trend is possible.
Study Reference(s) Location Periodsa Cases by time period RR (95% CI)b
Pre-ban Post-ban
S2 Barone-Adesi et al. (2006) Piedmont, Italy 2002–2004, 2005 3230
3473
3581
3655 0.96 (0.91–1.02)
S4 Bullen et al. (2006) New Zealand Dec 1996–Nov 2004, Dec 2004–Nov 2005 6480
6690
7235
7565
9055
9895
11,315
11,125
12,045 0.95 (0.92–0.97)
S6 Heinz et al. (2007) Boise, Idaho, USA Jul 2002-Jun 2004, Jul 2004-Jun 2005 NA NA 0.82 (0.63–1.06)c
S7 Juster et al. (2007) New York State, USA 1995–2002, 2004 44,683
45,449
44,961
44,651
45,889
48,010
48,015
47,943
45,412 0.92 (0.91–0.93)
S10 Barnett et al. (2009) Christchurch, New Zealand 2003–2004, 2005–2006 809
768
734
763
0.96 (0.82–1.13)
S11 Cesaroni et al. (2008) Rome, Italy 2002–2004, 2005 6935
7025
6890
6739 0.98 (0.93–1.02)
S12 Lemstra et al. (2008) Saskatoon, Saskatchewan, Canada Jul 2000–Jun 2004, Jul 2004–Jun 2005 351
323
363
341
312 0.90 (0.76–1.07)
S14 Vasselli et al. (2008) Three areas, Italyd 2002–2004, 2005 1056
1151
1182
1148 0.91 (0.82–1.01)
S15 Gasparrini et al. (2009) Tuscany, Italy 2002–2004, 2005 2319
2269
2254
2190 0.99 (0.92–1.07)
S16 Shetty et al. (2011) USA 1990–2004e NA NA 0.98 (0.93–1.03)f
S17 Villalbí et al. (2009) Barcelona, Spain 2004–2005, 2006 4686
4503
4127 0.95 (0.89–1.02)
S18 Di Valentino et al. (2010) Ticino, Switzerland Apr 13 2004–Apr 12 2006, Apr 13 2006–Apr 12 2008 659
673
564
569
0.82 (0.69–0.98)
S22 Sims et al. (2010) England Jul 2002–Jun 2007, Jul 2007–Sep 2008g NA NA 0.98 (0.96–0.99)h
S23 Séguret et al. (2013) France 2003–2006, 2008–2009 127,151
126,185
125,125
124,446
120,812
121,811
0.99 (0.98–1.00)
S24 Bonetti et al. (2011) Graubünden, Switzerland Mar 2006–Feb 2008, Mar 2008–Feb 2010 168
177i
133
132i
0.73 (0.51–1.04)
S25 Barone-Adesi et al. (2011) Italy 2002–2004, 2005 182,856
188,079
193,897
193,354 0.97 (0.96–0.98)
S26 Bruckman and Bennerr (2011) Ohio, USA 2005–2006, 2008–2009 22,632
21,608
20,623
19,351
1.06 (1.02–1.11)
S29 Gupta et al. (2011) Kanawha County, West Virginia, USA 2000–2002, 2004–2008 1637
1571
1530
1286
1256
1199
1062
0.99 (0.90–1.08)
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S30 Hahn et al. (2011) Lexington, Kentucky, USA 2001–2003, 2005–2006 473
490
450
426
425
0.97 (0.78–1.21)
S31 Herman and Walsh (2011) Arizona, USA May 2004–Apr 2007, May 2007–Apr 2008 9942
9725
9731
9943 1.04 (1.00–1.07)
S32 Hurt et al. (2012) Olmsted County, Minnesota, USA Ban 1 1995–2001, 2002–2003 175
191
140
169
145
163
186
162
173
[1.01 (0.85–1.21)]
Ban 2 2004–2006, 2008–2009 188
185
184
136
122
[0.76 (0.53–1.09)]
Combined 0.77 (0.52–1.15)j
S33 North Carolina Tobacco Prevention and Control Branch (2011) North Carolina, USA 2006–2009, 2010 9428
8317
8000 1.09 (1.03–1.15)
S35 Barr et al. (2012) 387 counties in 9 states, USA 1999–2008 NA NA 0.95 (0.94–0.96)k
S36 Christensen et al. (2012) Denmark Sep 2002-Aug 2007, Sep 2007-Aug 2009 16,536
16,509
15,830
15,445
15,224
14,819
14,731
1.00 (0.98–1.03)
S37 de Korte-de-Boer et al. (2012) South Limburg, Netherlands 2002–2003, 2004 NA NA 0.93 (0.80–1.09)l
S39 Huesch et al. (2012) New Jersey, USA May 2004-Mar 2006, May 2006-Mar 2007m 20,065
18,207
17,958 1.09 (1.05–1.13)
S41 Loomis and Juster (2012) Florida, USA Jan 1990-Jun 2003, Jul 2003-Dec 2006n NA NA 0.82 (0.72–0.91)o
S42 Roberts et al. (2012) Rhode Island, USA 2003–2004, 2006–2009 3041
2721
2427
2177
2194
1995
0.99 (0.92–1.06)
S43 Agüero et al. (2013) Girona, Spain 2002–2005, 2006–2008 613
653
647
631
601
605
686
0.91 (0.81–1.02)
S44 Gaudreau et al. (2013) Prince Edward Island, Canada 1998–2002, 2004–2007 388
403
424
413
388
406
419
416
0.94 (0.82–1.09)
S45 Sebrié et al. (2013) Uruguay Mar 2004-Feb 2006, Mar 2006-Feb 2008 2152
2195
1793
1806
0.80 (0.73–0.89)
Meta-analysis – random effects (n = 31 estimates) 0.97 (0.95–1.00)p
a The comma separates the pre-ban and post-ban periods. 12-month periods unless indicated.
b All estimates were calculated using formula 3, except where indicated.
c Author estimate adjusted additionally for weather and outdoor air quality, and based on daily data.
d Excluding Piedmont as already considered in study S2.
e Timing of bans varied.
f Author estimate for any smoking restrictions.
g Weekly data.
h Author estimate adjusted additionally for season, population size, temperature, ﬂu rates and Christmas holidays.
i Cases are in residents. Control data for Lucerne not used – see Appendix A.
j Combined effect of two bans.
k Author estimate adjusted additionally for age, sex and season.
l Estimate derived from comparison of 300 cases observed post-ban with an expected incidence of 322 based on an analysis adjusting for linear time trend, population size, ambient temperature, air pollution and inﬂuenza.
m 11-month periods ending in March.
n Quarterly data.
o Author estimate adjusted for linear time trend.
p Heterogeneity chisquared = 223.94 on 30 d.f., p < 0.001.
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Table 6
Effect of smoking bans on AMI admissions (or near equivalent) for studies with control data and multiple periods pre-ban; comparison of alternative estimates based on formula
3, with main estimates based on formula 2.
Study Reference(s) Periodsa Cases by time period RR (95% CI)
Pre-ban Post-ban Alternativeb Originalc
S1 Sargent et al. (2004) Jun 1998-Nov 2001, Jun 2002-Nov 2002d 33
37
42
50
24 0.42 (0.25–0.72) 0.38 (0.19–0.76)
S8 Khuder et al. (2007) Mar 1999–Feb 2002, Mar 2002-Feb 2005 81
69
61
87
66
65
1.03 (0.86–1.25) 0.98 (0.77–1.26)
S21 Moraros et al. (2010) 1999–2001, 2003–2004 1733
1761
1945
1815
1626
0.87 (0.78–0.97) 0.97 (0.88–1.08)
Meta-analysis – random effects (n = 3 estimates) 0.88 (0.56–1.40)e 0.96 (0.65–1.41)f
a The comma separates the pre-ban and post-ban periods. 12-month periods unless indicated.
b Estimate derived from data in ban area only using formula 3.
c Estimate derived using control data using formula 2, as given in Table 4.
d Only June to November considered in each year. 2003 ignored as ban rescinded in Dec 2002.
e Heterogeneity chisquared = 9.95 on 2 d.f., p < 0.01.
f Heterogeneity chisquared = 7.03 on 2 d.f., p < 0.05.
Table 7
Effect of smoking bans on AMI admissions (or near equivalent); comparison of alternative estimates based on rates with original estimates based only on numbers of cases.a
Study Reference(s) RR (95% CI) RR (95% CI)b
Estimates based on rates Estimates based on numbers
S2 Barone-Adesi et al. (2006) 0.98 (0.93–1.04) 0.96 (0.91–1.02)
S4 Bullen et al. (2006) 0.94 (0.91–0.96) 0.95 (0.92–0.97)
S7 Juster et al. (2007) 0.94 (0.93–0.95) 0.92 (0.91–1.03)
S10 Barnett et al. (2009) 0.96 (0.82–1.13) 0.96 (0.82–1.13)
S11 Cesaroni et al. (2008) 0.97 (0.93–1.02) 0.98 (0.93–1.02)
S12 Lemstra et al. (2008) 0.89 (0.75–1.06) 0.90 (0.76–1.07)
S14 Vasselli et al. (2008) 0.90 (0.81–1.00) 0.91 (0.82–1.01)
S15 Gasparrini et al. (2009) 1.00 (0.93–1.08) 0.99 (0.92–1.07)
S17 Villalbí et al. (2009) 0.96 (0.89–1.03) 0.95 (0.89–1.02)
S18 Di Valentino et al. (2010) 0.83 (0.69–0.99) 0.82 (0.69–0.98)
S23 Séguret et al. (2013) 0.99 (0.98–1.00) 0.99 (0.98–1.00)
S24 Bonetti et al. (2011) 0.73 (0.51–1.04) 0.73 (0.51–1.04)
S25 Barone-Adesi et al. (2011) 0.97 (0.96–0.98) 0.97 (0.96–0.98)
S26 Bruckman and Bennerr (2011) 1.06 (1.02–1.11) 1.06 (1.02–1.11)
S29 Gupta et al. (2011) 0.99 (0.90–1.08) 0.99 (0.90–1.08)
S30 Hahn et al. (2011) 0.97 (0.78–1.21) 0.97 (0.78–1.21)
S31 Herman and Walsh (2011) 1.04 (1.00–1.08) 1.04 (1.00–1.07)
S32 Hurt et al. (2012) 0.77 (0.52–1.15) 0.77 (0.52–1.15)
S33 North Carolina Tobacco Prevention and Control Branch (2011) 1.09 (1.03–1.15) 1.09 (1.03–1.15)
S36 Christensen et al. (2012) 1.01 (0.99–1.03) 1.00 (0.98–1.03)
S39 Huesch et al. (2012) 1.09 (1.05–1.13) 1.09 (1.05–1.13)
S42 Roberts et al. (2012) 0.99 (0.92–1.06) 0.99 (0.92–1.06)
S43 Agüero et al. (2013) 0.91 (0.81–1.02) 0.91 (0.81–1.02)
S44 Gaudreau et al. (2013) 0.95 (0.83–1.10) 0.94 (0.82–1.09)
Meta-analysis – random effects (n = 24 estimates) 0.99 (0.96–1.01)c 0.98 (0.96–1.01)d
a Based on studies where estimates adjusted for linear trend using formula 3 was possible, and where rate data were available.
b Adjusted for linear trend using formula 3.
c Heterogeneity chisquared = 160.62 on 23 d.f., p < 0.001.
d Heterogeneity chisquared = 191.21 on 23 d.f., p < 0.001.
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were not available to allow us to do this.
4.4. Our ﬁndings compared to those of others
Based on data for all 45 studies which provided estimates for
AMI admissions (or a near equivalent deﬁnition) our overall
estimate (random-effects) of the ban effect was 0.958 (95% CI
0.935–0.952), which became 0.974 (0.960–0.989) when we
excluded regional estimates where national estimates were avail-
able (to avoid overlap) and also excluded estimates where we
could not adjust for time trend. This is equivalent to a reduction
in risk following the ban of 2.6% (1.1–4.0%) and can be comparedwith our quite similar earlier estimate of 2.7% (2.1–3.4%). The esti-
mated reductions are less than reported in other meta-analyses.
Thus, Glantz (2008) estimated 19%, Lightwood and Glantz (2009)
17%, Meyers et al. (2009) 17%, Mackay et al. (2010) 10%, Lin et al.
(2013) 13%, while Tan and Glantz (2012) estimated 8% for work-
place bans, 5% for workplace and restaurant bans and 15% for the
most comprehensive bans.
Differences between our results and those reported in the meta-
analyses reported in 2008–2010 have been discussed in our earlier
review (Lee and Fry, 2011). The review by Lin et al. (2013) only
considers 15 of the 45 studies we consider, and includes only
ban effect estimates reported by the authors, making no attempt
to revise them to take control data into account or adjust for trend,
Table 8
Effect of smoking bans on AMI admissions (or near equivalent); comparison of estimates adjusted for quadratic and for linear trend.
Study Reference(s) Time points pre-ban Time points post-ban RR (95% CI) Quadratic adjustment RR (95% CI) Linear adjustment
S2 Barone-Adesi et al. (2006) 3 1 1.03 (0.89–1.20) 0.96 (0.91–1.02)
S4 Bullen et al. (2006) 8 1 0.94 (0.91–0.97) 0.95 (0.92–0.97)
S7 Juster et al. (2007) 8 1 0.89 (0.87–0.91) 0.92 (0.91–0.93)
S11 Cesaroni et al. (2008) 3 1 1.03 (0.93–1.14) 0.98 (0.93–1.02)
S12 Lemstra et al. (2008) 4 1 0.88 (0.64–1.20) 0.90 (0.76–1.07)
S14 Vasselli et al. (2008) 3 1 1.00 (0.78–1.30) 0.91 (0.82–1.01)
S15 Gasparrini et al. (2009) 3 1 0.96 (0.80–1.16) 0.99 (0.92–1.07)
S23 Séguret et al. (2013) 4 2 0.97 (0.95–0.98) 0.99 (0.98–1.00)
S25 Barone-Adesi et al. (2011) 3 1 0.97 (0.95–0.98) 0.97 (0.96–0.98)
S29 Gupta et al. (2011) 3 5 0.94 (0.85–1.04) 0.99 (0.90–1.08)
S30 Hahn et al. (2011) 3 2 0.96 (0.74–1.26) 0.97 (0.78–1.21)
S31 Herman and Walsh (2011) 3 1 1.00 (0.91–1.09) 1.04 (1.00–1.07)
S32 Hurt et al. (2012) 5, 3a 2, 2 0.67 (0.39–1.15)b 0.77 (0.52–1.15)
S35 Barr et al. (2012) NA NA 1.01 (0.98–1.03) 0.95 (0.94–0.96)
S36 Christensen et al. (2012) 5 2 0.99 (0.96–1.03) 1.00 (0.98–1.03)
S43 Agüero et al. (2013) 4 3 0.88 (0.77–1.00) 0.91 (0.81–1.02)
S44 Gaudreau et al. (2013) 5 3 0.95 (0.82–1.09) 0.94 (0.82–1.09)
Meta-analysis – random effects (n = 17 estimates) 0.96 (0.93–0.99)c 0.97 (0.95–0.99)d
a Two separate bans.
b Based on estimates of 0.79 (0.60–1.05) for ban 1 and 0.84 (0.53–1.35) for ban 2.
c Heterogeneity chisquared = 75.50 on 16 d.f., p < 0.001.
d Heterogeneity chisquared = 111.94 on 16 d.f., p < 0.001.
Table 9
Effect of smoking bans on AMI admissions (or near equivalent). Further meta-analyses of data considered in Tables 5–8.
Analysis number Estimates included No. of estimates RR (95% CI) Heterogeneity
chisquareda
Fixed effect Random effects
Main analysis
A1 All in Tables 3–5 47 0.966 (0.962–0.970) 0.958 (0.935–0.982) 347.1⁄⁄⁄
Variants of main analysis
A2 Use alternative not original estimates from Table 6 47 0.966 (0.962–0.970) 0.956 (0.932–0.981) 353.4⁄⁄⁄
A3 Use estimates based on rates not on numbers from Table 7 47 0.969 (0.965–0.974) 0.967 (0.948–0.987) 324.8⁄⁄⁄
A4 Use quadratic rather than linear estimates from Table 8 47 0.963 (0.957–0.970) 0.942 (0.913–0.971) 314.1⁄⁄⁄
A5 Use quadratic rather than linear estimates from
Table 8 only if at least 4 pre-ban points
47 0.963 (0.958–0.968) 0.948 (0.923–0.975) 322.6⁄⁄⁄
Exclusions from main analysis
A6 Exclude regional estimates where national estimates availableb 19 0.972 (0.967–0.977) 0.972 (0.957–0.986) 117.7⁄⁄⁄
A7 Exclude Table 3 estimates 40 0.968 (0.964–0.973) 0.972 (0.950–0.995) 269.3⁄⁄⁄
A8 Exclusions as in analyses A6 and A7 14 0.975 (0.969–0.980) 0.974 (0.960–0.989) 46.2⁄⁄⁄
a Coded as ⁄⁄⁄p < 0.001, ⁄⁄p < 0.01, ⁄p < 0.05, (⁄) p < 0.1, NS p > 0.1.
b Based on studies S4, S12, S13, S16, S17, S18, S22, S23, S24, S25, S28 (two estimates), S34, S36, S37, S40, S43, S44, and S45. The national estimate for the USA from study
S16 is preferred to that from study S19 as it was adjusted for trend.
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linear trend, citing Barr et al. (2012). The review by Tan and
Glantz (2012) is more comprehensive, including a large number
of the studies we consider. However, there are some differences
in approach. Thus, for studies that give results by age, they use
results for <65 years of age, as the risk of CHD from smoking is
known to decrease with age, whereas we use all age results, for
consistency with the other studies. They also give separate sex
results, where available, whereas we prefer combined sex results,
and they never use estimates based on control data, strangely pre-
ferring simple after/before comparisons within the ban area. We
did attempt to compare Tan and Glantz’s estimates with ours
(detailed results now shown), where this was possible, and found
numerous differences. The reason for this was not always clear,
as they did not explain in detail how their estimates were derived.
Of 31 cases where direct comparison was possible, the ban effect
was the same in only six, and in as many as 20 of the remaining
25 they calculated a stronger ban effect than we did. The most
notable difference was for study S33 where their estimate, ignoring
trend, was 0.79, and ours, adjusting for trend, was 1.09. Other nota-
ble differences were seen for study S31 (0.84 vs 1.04) and study
S27 (0.73 vs 0.88).4.5. New features
Our review extends and modiﬁes our methods in various ways.
4.5.1. Quadratic vs linear adjustment for time trend
Following the report by Barr et al. (2012) that estimates derived
assuming the underlying trend is linear may be substantially
biased if a non-linear trend exists pre-ban, we attempted to derive
estimates adjusted for a quadratic trend. We were limited by only
16 other studies providing data for at least three time periods
pre-ban, the minimum number of periods to ﬁt a quadratic trend.
Moreover, over half of these provided data for only three periods.
Noting that there seemed to be no consistent directional difference
between quadratic and linear estimates, with random-effects
overall estimates for the 17 studies quite similar (see Table 8), that
the quadratic estimates have a wider 95% CI than do the linear
estimates, sometimes quite substantially, and that quadratic esti-
mates are not available for many studies, we decided to keep to
our original approach (Lee and Fry, 2011) and not include qua-
dratic estimates in our main analyses. We do, however, accept
the premise of Barr et al. (2012) that this is not totally desirable
if trends actually are non-linear, and that, especially where the
Table 10
Effect of smoking bans on AMI admissions (or near equivalent). Variation in relative risk by different factors.a
Factor Level No. of estimates RR (95% CI) Heterogeneity between levels
Fixed effects Random effects
Weight of estimate >10,000 5 0.963 (0.959–0.968) 0.961 (0.911–1.014) p = 0.085
1001–10,000 12 0.988 (0.979–0.998) 0.990 (0.954–1.028)
501–1000 6 0.919 (0.892–0.947) 0.916 (0.861–0.976)
101–500 14 0.908 (0.879–0.938) 0.902 (0.854–0.952)
<100 10 0.808 (0.732–0.891) 0.807 (0.702–0.928)
Source of estimateb Table 3 7 0.940 (0.925–0.955) 0.911 (0.865–0.959) p = 0.130
Table 4 9 0.841 (0.788–0.897) 0.831 (0.743–0.929)
Table 5 31 0.969 (0.965–0.973) 0.974 (0.949–1.000)
Region USA 23 0.957 (0.950–0.964) 0.978 (0.944–1.014) p = 0.126
Western Europe 17 0.974 (0.967–0.980) 0.956 (0.923–0.989)
Other 7 0.926 (0.908–0.945) 0.901 (0.844–0.963)
Pre-ban periodc Up to 18 months 9 0.932 (0.917–0.948) 0.885 (0.836–0.938) p = 0.131
19 to 30 months 17 1.012 (0.994–1.031) 0.975 (0.927–1.025)
31 to 42 months 7 0.972 (0.964–0.979) 0.983 (0.925–1.044)
>42 months 11 0.965 (0.958–0.971) 0.960 (0.918–1.004)
Post-ban periodc Up to 18 months 20 0.961 (0.956–0.966) 0.958 (0.924–0.993) p = 0.065
19 to 30 months 12 0.989 (0.980–0.998) 0.951 (0.899–1.005)
31 to 42 months 9 0.853 (0.812–0.895) 0.856 (0.782–0.937)
>42 months 3 0.998 (0.947–1.052) 0.997 (0.890–1.116)
Change in restrictionsd <40% 8 1.023 (1.006–1.040) 1.022 (0.967–1.081) p = 0.093
40–60% 15 0.963 (0.958–0.968) 0.959 (0.929–0.990)
>60% 9 0.968 (0.955–0.980) 0.954 (0.914–0.996)
Lower age limit <21 34 0.975 (0.970–0.980) 0.952 (0.921–0.983) p = 0.100
21–64 11 0.944 (0.934–0.953) 0.949 (0.899–1.003)
65+ 2 0.957 (0.946–0.968) 0.960 (0.877–1.051)
Upper age limit None 41 0.966 (0.962–0.971) 0.957 (0.932–0.983) p = 0.857
64–84 6 0.960 (0.935–0.985) 0.955 (0.890–1.025)
a Based on all estimates in Tables 6–8, i.e. main analysis in Table 9.
b Random effects estimates differ slightly from those given in Tables 3–5 due to differing residual error.
c Excludes studies S16, S29 and S35 where this varied according to the ban.
d Excludes 15 studies where data were unavailable (see Table 2).
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bias.
4.5.2. Modifying the method of adjusting for trend
The approach used in our earlier paper (Lee and Fry, 2011) only
used the pre-ban data to determine the shape of the time trend.
Here we estimate the shape of the underlying trend using pre-
and post-ban data. While the estimates are unchanged where there
is only one post-ban period, they differ when there are multiple
post-ban periods. In preliminarywork (not reported here),we found
that the revised method produced more stable estimates when
adjusting for quadratic trend, as it incorporated more information.
Our method assumes the ban effect is simply to multiply subse-
quent risk by a factor, without affecting the underlying slope of the
trend. Lack of clear evidence of a relationship between the length
of post-ban period and the estimated ban effect to some extent
supports this assumption, though it must be admitted that the
effect may be less simple than we have posited. We have not
attempted to ﬁt an alternative model in which the ban also affected
the underlying trend, partly as this could only be ﬁtted to studies
with multiple post-ban periods, and partly as it seems likely that
the estimates could be unstable and difﬁcult to interpret where
there are limited post-ban periods.
4.5.3. Numbers or rates
We also investigated the effect of using population data and
thus rates, where available, to estimate ban effects, rather than
assuming there was no meaningful change in the at risk popula-
tion. As shown in Table 7, and in the alternative analysis in Table 9,
using estimates based on rates rather than numbers had little
effect, so justifying the assumption we used earlier (Lee and Fry,2011). In any case, a marked change in population in a short period
is likely to be associated with immigration or emigration, and the
changing make-up of the population may have introduced other
factors affecting the outcome apart from the ban. Furthermore, if
the change in population is linear, the numbers of cases predicted
post-ban by formulae 3 will still be correct.
4.5.4. Subgroup analyses
We included analyses comparing estimates of the ban effect by
various factors (see Table 10). There was a greater reduction in
smaller studies, possibly related to small studies that fail to ﬁnd
an effect being less likely to report their results. This bias may also
explain the greater reductions in the studies in Table 4 (using con-
trol populations) which were typically conducted at US county
level.
We also observed that the ban effect was only seen in studies
with larger changes in restrictiveness score following the ban,
and not seen at all where the change was smallest. Although the
method used to rate the restrictiveness of the bans was not fully
consistent (being based on published ratings using different
schemes in the US and Europe, and on our own estimates else-
where), this ﬁnding seems to align with what one might expect
if there were a true small reduction in risk associated with the
ban. We found no evidence that the estimated ban effect varied
with the overall age of the population studied.
4.6. Plausibility of a ban effect
As discussed in more detail earlier (Lee and Fry, 2011), there are
various reasons why one might expect a true effect of a smoking
ban on AMI rates. These include:
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2004; Yusuf et al., 2004) that declines quite rapidly on quitting
(Lee et al., 2012; US Surgeon General, 1990),
 Increased risk in nonsmokers exposed to environmental
tobacco smoke (ETS) (Glantz and Parmley, 1991, 1995; He
et al., 1999; Law et al., 1997; Lee et al., 2013),
 Evidence that smoking bans lead to a reduction in the preva-
lence of smoking and in consumption per smoker (Bauer
et al., 2005; Fichtenberg and Glantz, 2002; Gallus et al., 2006;
Heloma and Jaakkola, 2003; Lemstra et al., 2008), and
 Evidence that smoking bans lead to a marked reduction in coti-
nine levels in nonsmokers (Haw and Gruer, 2007; Pechacek
et al., 2007).
This picture is reinforced by the new evidence that ban effects
seem greater if the change in restrictiveness following a ban is
greater. One study (S31) reported similar results in their detailed
analyses.
It is also clear from calculations carried out earlier (Lee and Fry,
2011) that any expected drop in heart disease rates following a ban
would be quite modest, and not of the order of almost 20% claimed
in some early reviews (Glantz, 2008; Lightwood and Glantz, 2009;
Myers et al., 2009).
However, various uncertainties remain, due to the weakness of
much of the published evidence on bans, the small magnitude of
the estimated effect, and the possibilities of bias.4.7. Limitations
One limitation of this assessment clearly arises from the nature
of the results available in the published literature, presented in
various ways, some making precise analysis difﬁcult, and consis-
tency difﬁcult to achieve.
Another limitation is that the extent to which bans have been
complied with is not taken into account. This is rarely reported
in these studies. We have not sought independent sources for such
data. Evidence that ban effects are greater where compliance is
better would strengthen the argument that the effect is a real
one and not due to bias.
A further concern relates to changes in diagnosis. As the
national study in Italy (S25) restricted attention to data for years
from 2002, diagnostic changes having been introduced in 2000,
and as the annual data for one of the regional studies in Italy
(S11) was consistent with a different trend before 2002, we
decided to ignore pre-2002 data for all the regional studies in Italy
(S2, S11, S14, S15). However, we have not attempted any similar
exclusion of data for other countries, nor investigated whether
any other such diagnostic or classiﬁcation changes are relevant.
Pre-2002 data are used in relatively few studies (S4, S7, S12, S16,
S29, S30, S32, S35, S41, S44), and in some of those (S16, S35,
S41) the annual data are not available to correct our estimates.
Variation in endpoints used is also another issue that could, per-
haps, be given more detailed attention.5. Conclusions
Our updated review conﬁrms the existence of important weak-
nesses in many published studies and meta-analyses. In contrast to
various meta-analyses that claim large effects of introducing bans
on incidence of AMI, we demonstrate that estimated effects are
much smaller, if a valid and consistent approach, as far as possible
taking account of time trends and control data, is used. Based on all
45 studies considered, the reduction is estimated to be by 4.2%
(95% CI 1.8–6.5%). Excluding regional estimates where national
estimates are available, and excluding studies where adjustmentfor the underlying trend was not possible, this reduces further, to
2.6% (1.1–4.0%). This reduction is consistent with a true effect on
heart disease resulting from the ban modifying cigarette consump-
tion and ETS exposure, an effect which would be important on a
public health level. However, various uncertainties remain, due
to the weakness of much of the published evidence on bans, the
small magnitude of the estimated effect, and the possibilities of
bias.
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ban, comparisons made and the main ban effect estimates reported
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